Subscribe
eNewsletter
Ready to get certified?
Free CDCES Coach App
Download
Free Med Pocket Cards
eNewsletter
Free CDCES Coach App
Free Med Pocket Cards
Our September 21st Question of the week quizzed test takers on Intensive Insulin Therapy with A1c 6.2%. Three quarters (74%) of respondents, chose the best answer. We are excited to … Continue reading Rationale of the Week | Intensive Insulin Therapy with A1c 6.2%
As a diabetes specialist at a local hospital, one of your quality improvement goals is to prevent nocturnal hypoglycemia. Which of the of following policy changes would most likely lower … Continue reading Question of Week | Best strategy to Prevent Hypo in Hospital?
Did you know that Toujeo U-300 insulin pens are good for 56 days once opened? And that the max dose for Tresiba U-200 FlexTouch Pen is 160 units? For our … Continue reading Concentrated Insulin and GFR Guidelines for SGLT2s
Our September 14th Question of the week quizzed test takers on a new med. Less than half, 47% of respondents, chose the correct answer. This was a hard question since … Continue reading Rationale of the Week | What Teaching Tip for New Med – finerenone?
The Food and Drug Administration (FDA) just approved another GLP-1 RA for use in children ages 10-17 with diabetes. The injectable extended-release exenatide (Bydureon) is now the second glucagonlike peptide-1 … Continue reading Diabetes Medication approved for Kids
What is the best response in this situation? Start HR on an insulin pump and CGM to prevent hypoglycemia. Discuss de-intensifying insulin regimen. Using a strength-based approach, reinforce the importance … Continue reading Question of Week | Intensive Insulin Therapy with A1c 6.2%
Attention Diabetes Educators and Specialists: Do you know an adult living with Type 1 Diabetes and an A1c of 7.5% or greater? Please invite them to join the EMBARK Study, … Continue reading Know someone with Type 1 Diabetes? We can offer help!
Since heart disease is the leading cause of death in people with diabetes, these new treatment options including PCSK9 Inhibitors and ACL Inhibitors, offer hope of decreasing cardiovascular mortality and … Continue reading New Lipid and Kidney Protection Meds Approved